Santo Domingo.- To propel holistic growth in nursing, the Diabetes, Obesity, and Specialties Medical Center (CEMDOE) has launched a training initiative. This program focuses on bolstering competencies, spanning technical proficiency and interpersonal abilities, in line with its recently introduced Nursing Management Model.

Comprising eight core pillars, the program features five modules dedicated to fostering these competencies, ensuring that CEMDOE’s nursing personnel maintain a standard of excellence in care provision. This initiative adheres to the benchmarks set by the Joint Commission International, underscoring the medical center’s commitment to upholding international standards of quality and patient safety.

The conceptualization and design of this program were spearheaded by Dr. Berniza Calderón, Senior Research Manager; Damaris Durán, Nursing Manager; Gricely Pozo, Medical Director; Maril Núñez, Director of Human Management and Transformation; and Nilaine Alejo, Senior Human Management Manager.

“This launch signifies a significant stride in our continuous mission to enhance the healthcare experience, acknowledging wholeheartedly the pivotal role that nurses play in attending to the needs of our patients and their families,” elucidated Dr. Calderón.

Additionally, the specialist underscored that in the Dominican Republic, the ratio stands at fewer than 4 nurses for every 10,000 inhabitants, with only 30% of those employed in the healthcare sector possessing a university degree.

As for the supplementary workshops integrated into the program, they encompass a diverse array of topics, including care plan design, the significance of reporting and analyzing patient safety incidents, tools for patient and family education, evidence-based nursing practices, and the provision of compassionate care.

CEMDOE undertakes this endeavor with the overarching objective of elevating the quality of care received by its patients throughout the entirety of their healthcare journey, recognizing the indispensable role that nursing staff play in facilitating this process.

The pop star, 34, is currently taking a break from the international leg of her sold-out tour and has been pictured enjoying a romantic getaway with boyfriend Travis Kelce in the Bahamas.

The trials are carried out by Bharat Biotech in close collaboration with Biofabri.
Trials to evaluate the safety and immunogenicity of MTBVAC have started with a
pivotal safety, immunogenicity and efficacy trial planned to start in 2025.

After more than three decades of research, Esteban Rodriguez, CEO of Biofabri
says, "It is a giant step to test in adults and adolescents in the country where
28% of the world’s TB cases accumulate and concludes that more effort and
funding is needed to combat TB, which remains one of the world’s leading
infectious causes of death, especially in India."

Dr. Krishna Ella, Executive Chairman Bharat Biotech added, “Our quest for a
more effective vaccine against Tuberculosis received a big boost, with
clinical trials in India. Our goal to develop TB vaccines to prevent disease in adults
and adolescents has taken a big step. We are honoured to partner with
BioFabri, Dr. Esteban Rodriguez and Dr. Carlos Martin in this noble effort to
reinvent TB vaccines.”

As per the release, the MTBVAC vaccine has passed several milestones before entering clinical
trials in India. The first is that after the recent completion of a Phase2 dose finding trial, a
double-blind, controlled Phase3 clinical trial in newborns has started in 2023,
comparing the vaccine with the current BCG vaccine. 7,000 newborns from South
Africa, 60 from Madagascar and 60 from Senegal will be vaccinated. To date,
more than 1,900 babies have been vaccinated. The aim is to assess the immunogenicity and efficacy of MTBVAC which is
administered intradermally to infants on the first day of life.

Vaccination began at a time of setback in the global fight against TB. Health
restrictions imposed during the COVID-19 pandemic led to an increase in
infections and a decrease in diagnosis and treatment. As a result, annual TB
deaths have risen to over 1.6 million.

This Phase3 neonatal project, partially funded by the European Union through its
EDCTP (European & Development Countries Clinical Trial Partnership)
programme, is being coordinated by Biofabri, as part of a consortium that also
includes the University of Zaragoza (Unizar), TuBerculosis Vaccine Initiative
(TBVI), The University of Cape Town (UCT)/SATVI, Wits VIDA Health Consortium
(WHC), Stellenbosch University (SUN-FAMCRU), Enhancing Care Foundation
(ECF), Center de Recherche Biomedicale Espoir Pour La Santé (CRB-EPLS,
Senegal) and Institut Pasteur de Madagascar (IPM).

"Another important milestone is that after completing a dose escalation trial in HIV
uninfected adults, a Phase2 study in HIV infected adults has started in 2024 to
determine whether MTBVAC is safe in this population. This ongoing trial at 16
sites in South Africa – involving the vaccination of 276 adults – is evaluating safety and immunogenicity in HIV-negative and HIV-positive adults and adolescents
vaccinated with MTBVAC," the release stated.

A Phase2b efficacy study in adolescents and adults is planned to start in the
second half of 2024 in Sub-Saharan Africa.

The studies in adolescents and adults in Sub-Saharan African are led by the
American institution IAVI. The Phase2 HIV safety study is carried out by HIV
Vaccine Trials Network (HVTN) and is funded by the Division of AIDS (DAIDS),
National Institute of Allergy and Infectious Diseases (NIAID), National Institutes
of Health (NIH), Department of Health and Human Services (DHHS). The
Phase2b efficacy study will be carried out by IAVI and will be funded by BMGF
and Open Philanthropy.

This vaccine was developed in the laboratory of the University of
Zaragoza, which has been part of CIBERES since its creation, in collaboration
with Dr Brigitte Gicquel of the Pasteur Institute in Paris. The University of
Zaragoza has the Spanish biotechnology company BIOFABRI as an industrial
partner.

Read also: Bharat Biotech Gets CDSCO Panel Nod To Manufacture Rotavirus Vaccine Live Attenuated, Oral

View the full post Covid-19 After Action Review can result in improvement on NOW Grenada.

Foreign Affairs Minister Hugh Todd on Monday confirmed that government has given approval to a private company to hire health care workers, and said that the company could now do so from any other country not just Bangladesh. “They have amended that…It can be Latin America and the Caribbean, it could be Asia. It is ...

The team from the Vector Control Unit will fog areas in St Michael, for the entire week, starting on Monday, March 25, with Erdiston Drive, Sunset Drive, Sunrise Drive, Pine Gardens, Elizabeth Drive, Pine Hill Road, Cedar Hill Road, and surrounding communities.

The following day, Tuesday, March 26, the Unit will visit Lascelles Terrace, Princess Royal Avenue, Pine Plantation Road, and neighbouring districts.

It will then go into Barclays Terrace, Wildey Avenue Nos.1 to 8, Meadow Road, Wharfdale Road, Golden Rock Road, and Newton Crescent, on Wednesday, March 27.

The fogging exercise for the week will conclude on Thursday, March 28, when the Unit sprays Smith Avenue, Main Port Road, Stanley Terrace, Golden Rock Road, and Pine East West Road.

Fogging takes place from 4:30 to 8:30 p.m. daily. Householders are reminded to open their windows and doors to allow the spray to enter. Children should not be allowed to play in the fog.

Members of the public are advised that the completion of scheduled fogging activities may be affected by events beyond the Unit’s control. In such circumstances, the Unit will return to communities affected in the soonest possible time.

The post Fogging schedule for March 25 – 28 appeared first on Barbados Today.

Here are the top health news for the day :

PM Modi inaugurates modern hospital built with Indian assistance in Bhutan

Prime Minister Narendra Modi inaugurated the state-of-the-art hospital, Gyaltsuen Jetsun Pema Wangchuk Mother and Child Hospital built with Indian assistance showcasing the robust development cooperation between India and Bhutan.

The Gyaltsuen Jetsun Pema Wangchuk Mother and Child Hospital is a state-of-the-art 150-bedded facility that has been built with the assistance of the Government of India in Thimphu.

For more information, click on the link below:

PM Modi Inaugurates Gyaltsuen Jetsun Pema Wangchuk Mother And Child Hospital

Pharma donations to parties: Electoral bonds analysis

With the State Bank of India (SBI) finally submitting crucial data on the electoral bonds to the Election Commission (EC) yesterday, the EC made public a fresh data set of electoral bonds, including their alpha-numeric numbers that can help match their purchasers with the political parties that received the funds.

Two separate lists of the donors and the recipients have been published by the poll panel on its website after the details were submitted to it by the SBI earlier in the day as per a Supreme Court order.

For more information, click on the link below:

Electoral Bonds Data: Which Pharma, Healthcare Company Made Donations To Which Party?Illegal sex determination racket busted in Gujarat

Busting an illegal sex determination racket in Gujarat’s Sabarkantha district, a doctor was recently caught red-handed for allegedly determining the sex of the foetus of a pregnant woman at Drupad Hospital in exchange for Rs 20,000.

Afterwards, the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Cell of Rajasthan on Wednesday arrested the doctor along with an agent following a decoy operation.

For more information, click on the link below:

Illegal Sex Determination Racket Busted In Gujarat, Doctor Arrested

Patients with these cancers often present with late-stage disease, undergo surgery and are then treated with platinum-based chemotherapy. They may become resistant to this treatment and require another therapy, such as ELAHERE.

"The full FDA approval of ELAHERE for eligible patients with ovarian cancer represents the culmination of years of work by the ImmunoGen team. ELAHERE is the first and only antibody-drug conjugate (ADC) approved in the U.S. for this difficult-to-treat malignancy," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie.

ELAHERE was first granted FDA accelerated approval in November 2022 and the conversion to full approval is based on data from the confirmatory Phase 3 MIRASOL trial. This trial compared ELAHERE to investigator's choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC) whose tumors express high levels of FRα and who have been treated with up to three prior therapies. The primary endpoint of MIRASOL was progression-free survival (PFS) by investigator assessment and key secondary endpoints included objective response rate (ORR) and overall survival (OS).

"As the first treatment to show a statistically significant overall survival benefit in patients with platinum-resistant ovarian cancer, ELAHERE provides an effective new option for patients with folate receptor alpha positive tumors. These patients previously had very limited options and ELAHERE changes that," said Kathleen Moore, deputy director and associate director of clinical research at the Stephenson Cancer Center of The University of Oklahoma and MIRASOL principal investigator.

MIRASOL is a randomized Phase 3 trial of ELAHERE versus investigator's choice (IC) of single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan). Eligibility criteria include patients with PROC whose tumors express high levels of FRα, using the Ventana FOLR1 Assay, and who have been treated with up to three prior regimens. The primary endpoint of this trial is progression-free survival (PFS) by investigator assessment. Key secondary endpoints include objective response rate (ORR) and overall survival (OS). The trial enrolled 453 patients. Patients were stratified by number of prior lines of therapy (14% had one prior line of therapy, 39% had two prior lines of therapy, and 47% had three prior lines of therapy) and by IC chemotherapy, with paclitaxel as the most commonly chosen (41%), followed by PLD (36%) and topotecan (23%). 62% of patients received prior bevacizumab; 55% received a prior PARP inhibitor.

Based on current results:

• OS hazard ratio (HR) was 0.67 (95% confidence interval [CI]: 0.50, 0.88; p=0.0046), representing a 33% reduction in risk of death in the ELAHERE arm compared to the IC chemotherapy arm.
• PFS HR was 0.65 (95% CI: 0.52, 0.81; p<0.0001), representing a 35% reduction in the risk of tumor or cancer progression in the ELAHERE arm compared to IC chemotherapy.
• ELAHERE showed overall fewer Grade 3+ adverse events and a lower rate of discontinuations due to adverse events when compared to the IC chemotherapy control group.

Ovarian cancer is the leading cause of death from gynecological cancers in the United States. Each year, approximately 20,000 patients are diagnosed. Most patients present with late-stage disease and will typically undergo surgery followed by platinum-based chemotherapy. Unfortunately, the majority of patients eventually develop platinum-resistant disease, which is difficult to treat. In this setting, standard of care single-agent chemotherapies are associated with low response rates, short durations of response, and significant toxicities.

ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. 

The Marketing Authorization Application (MAA) for ELAHERE in Europe has been accepted by the European Medicines Agency (EMA). Regulatory submissions for ELAHERE are also under review in multiple other countries.

Read also: FDA approves new dermal filler for hollows in upper face